Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the ECC Webcasts. By clicking the button below you are declaring and confirming that you are a healthcare professional.

You are here

Maximizing Clinical Management for Your Patients: Advances in Cancer Care with MKIs (AJ)

Sun 27 Sept. / 13:00 to 14:30 / Hall A4

Increased understanding of the molecular pathogenesis of cancer has led to development of several multikinase inhibitors (MKIs) designed to target specific molecular alterations and dysregulations of oncogenic pathways implicated in tumorigenesis. In the past decade, MKIs such as sorafenib, which targets vascular endothelial growth factor receptor–mediated tumor angiogenesis, have been approved for various tumor types, including renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). More recently, MKIs have also demonstrated efficacy in patients with differentiated thyroid cancer (DTC) who are refractory to radioactive iodine (RAI) therapy. Nevertheless, critical questions remain. Current gaps in the understanding of MKI treatment include optimal timing of treatment initiation, appropriate dosing and duration of treatment, and assessment of treatment response. Conventional tumor assessment criteria, such as Response Evaluation Criteria in Solid Tumors (RECIST), may not be sufficiently sensitive to determine treatment benefit from targeted therapies. Identifying a better approach to assess the effects of MKIs may help optimize treatment decisions and improve patient outcomes. Additionally, real-world data reveal discrepancies between treatment guidelines and daily practice, indicating the need to provide education and standardize treatment practices according to evidence-based clinical practice guidelines. (G.MKT.SM.ON.10.2015.1453)


Search this site

Search form


Register to our E-Alert to stay informed of new clinical research and cases published on this platform.